Survival and prognostic factors analysis of primitive neuroectodermal tumor
10.3760/cma.j.issn.0253-3766.2018.08.010
- VernacularTitle: 原始神经外胚层肿瘤预后因素分析
- Author:
Jie SHEN
1
;
Yan YUAN
2
;
Ke HU
1
;
Xin LIAN
1
;
Xiaorong HOU
1
;
Shuai SUN
1
;
Junfang YAN
1
;
Zhikai LIU
1
;
Fuquan ZHANG
1
Author Information
1. Department of Radiation Oncology, Peking Union Medical College Hospital, Beijing 100730, China
2. Department of Radiation Oncology, Nanshi Hospital of Nanyang, Nanyang 473005, China
- Publication Type:Clinical Trail
- Keywords:
Primitive neuroectodermal tumor;
Surgery;
Chemotherapy;
Radiotherapy;
Prognosis
- From:
Chinese Journal of Oncology
2018;40(8):614-618
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical features and prognosis of primitive neuroectodermal tumor (PNET).
Methods:The clinical data of 99 patients with PNET from February 1, 1998 to February 1, 2017 were retrospectively analyzed. Univariate analysis was performed using Kaplan-Meier and Log rank test. Multiviate Cox regression was applied to analyzed independent prognostic factor for patient survival.
Results:Among the 99 patients, 81 were peripheral PNET(pPNET) and 18 were central PNET (cPNET) . Biopsy was performed exclusively in 16 cases, with R0 resection in 61 cases, with R1 resection in 4 cases, and with R2 resection in 18 cases. Twelve patients underwent surgery only, nine had chemotherapy only, and one received radiotherapy only. There were 72 patients who had combined treatment including chemotherapy, and 48 patients had combined therapy including radiotherapy. The one-year, three-year and five-year overall survival(OS) rates of the 99 PNET patients were 79.2%, 63.9% and 56.1% respectively, and median OS time was 14.0 months. The one-year, three-year and five-year progression free survival (PFS) rates of these patients were 42.7%, 25.7% and 19.8% respectively, and median PFS time was 8.0 months. The univariate analysis revealed that lymph node metastasis, surgical resection, numbers of cycles of chemotherapy and radiotherapy dose were the main factors affecting the OS (all P<0.05). Gender, age, lymph node metastasis, staging, and chemotherapy cycles were related to PFS in PNET patients (P<0.05). Multivariate analysis showed that the degree of surgical resection, chemotherapy cycle, and radiotherapy dosage were independent influencing factors of OS in PNET patients (risk ratio=1.856, 0.398, and 0.408, respectively, all P<0.05), and gender was an independent factor influencing PFS in PNET patients (risk ratio=0.494, P<0.05).
Conclusions:Comprehensive therapy is the main therapy for PNET patients. The surgical resection, cycles of chemotherapy and radiotherapy dosage are independent prognostic factors for patient′s OS.
